Filtering by:
GeneticsColon and Endometrial Cancer Survivor Speaks Out About Lynch Syndrome
Jill Chang says she always knew she might get cancer some day. It seemed to run in the family. But she never dreamed she’d be diagnosed with cancer at age 30.
Study: High BMI + Certain Genetic Makeup = Sharp Increase in Women’s Colorectal Cancer Risk
For women with a certain genetic makeup, being overweight or obese significantly raises the risk for colorectal cancer, according to a recent study published in JNCI: Journal of the National Cancer Institute.
Future Defenses Against Colorectal Cancer May Include a Vaccine and Genetic Engineering
To help both the death and diagnosis rates of colorectal cancer drop—and to help those who develop it survive and thrive—the American Cancer Society (ACS) funds the research of scientists across the country who use the latest evidence and cutting-edge technology to help prevent and treat CRC. Here are two of their stories.
Cancer Research Insights from the Latest Decade, 2010 to 2020
Here’s a look at some of the significant advances in cancer research from the past 10 years that are helping to save lives now – and how American Cancer Society staff and funded researchers have contributed to each one.
Cancer Patients May Not Be Told About Costs of Genomic Testing
As of 2016, more than 200 targeted therapies (also called precision medicines) were available in the United States, and more than 2,000 were in the last stages of development—half of them to treat cancer. For many of these drugs, doctors first use genomic testing of the cancer cells to get an idea of whether the treatment will work. Yet, nearly 1 in 4 oncologists rarely or never mention costs when they talk about the need for genomic testing with their cancer patients, according to a new study led by American Cancer Society (ACS) investigators.
Should You Get Genetic Testing for Cancer Risk?
Most cancers are not caused by inherited gene mutations. But if cancer runs in your family, you may want to consider genetic testing options.
FDA Approves Rozlytrek (Entrectinib) for Tumors With Certain Genetic Markers
The US Food and Drug Administration (FDA) has approved Rozlytrek (entrectinib) for adults and adolescents with tumors that test positive for NTRK gene changes, which can help cancerous tumors grow.
Not All Black Women in the United States Have the Same Level of Risk for Triple-Negative Breast Cancer
We’ve known for a while that triple-negative breast cancer is more common in Black women in the United States, compared to other groups. The news is the prevalence varies significantly depending on where these women were born. American Cancer Society (ACS) researchers found that among Black women, those born in the US and Western Africa were diagnosed more often with triple-negative breast cancer than women born in East Africa. The authors published their findings in Cancer, an ACS peer-reviewed journal.